Characteristics of hormone therapy, cognitive function, and dementia: The prospective 3C study

Neurology

Volumn 73, Issue 21, 2009, Pages 1729-1737

  Ryan, J ^a,b,c   Carriere I ^a,b   Scali, J ^a,b   Dartigues, J F ^a   Tzourio, C ^a,d   Poncet, M ^e   Ritchie, K ^a,b   Ancelin, M L ^a,b  

^a INSERM   (France)

^b University of Melbourne ^*

^c UNIVERSITY OF MELBOURNE   (Australia)

^d SORBONNE UNIVERSITÉ   (France)

^e TIMONE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GESTAGEN; MEDROGESTONE; PROGESTERONE; PROMEGESTONE; APOLIPOPROTEIN E;

AGED; ALLELE; ARTICLE; COGNITION; DEMENTIA; DRUG EFFECT; EPOE EPSILON4 GENE; FEMALE; FRANCE; GENE; GENETIC LINKAGE; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; TASK PERFORMANCE; TREATMENT DURATION; CLINICAL TRIAL; COGNITIVE DEFECT; COHORT ANALYSIS; ESTROGEN THERAPY; GENETICS; METHODOLOGY; MULTICENTER STUDY; NEUROPSYCHOLOGICAL TEST; RETROSPECTIVE STUDY; STATISTICAL MODEL;

AGED; AGED, 80 AND OVER; APOLIPOPROTEINS E; COGNITION DISORDERS; COHORT STUDIES; DEMENTIA; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; LOGISTIC MODELS; NEUROPSYCHOLOGICAL TESTS; RETROSPECTIVE STUDIES;

EID: 73349108800     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181c34b0c     Document Type: Article

References (39)

1. Ancelin ML, Ritchie K. Lifelong endocrine fluctuations and related cognitive disorders. Curr Pharm Design 2005; 11:4229-4252.
2. Sherwin BB, Henry JF. Brain aging modulates the neuro-protective effects of estrogen on selective aspects of cognition in women: a critical review. Front Neuroendocrinol 2008;29:88-113.
3. Sherwin BB. Estrogen and cognitive functioning in women. Endocr Rev 2003;24:133-151.
4. Ryan J, Scali J, Carriere I, Ritchie K, Ancelin ML. Hormonal treatment, mild cognitive impairment and Alzheimer's disease. Int Psychogeriatr 2008;20:47-56.
5. Henderson VW, Sherwin BB. Surgical versus natural menopause: cognitive issues. Menopause 2007;14:572-579.
6. The 3C Study Group. Vascular factors and risk of dementia: design of the three city study and baseline characteristics of the study population. Neuroepidemiology 2003;22: 316-325.
7. Dufouil C, Richard F, Fievet N, et al. APOE genotype, cholesterol level, lipid-lowering treatment and dementia. Neurology 2005;64:1531-1538.
8. Ryan J, Carriere I, Scali J, Ritchie K, Ancelin ML. Lifetime estrogen exposure and cognitive functioning in later life. Psychoneuroendocrinology 2009;34:287-298.
9. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV. Washington, DC: American Psychiatric Association; 1994.
10. Commenges D, Letenneur L, Joly P, Alioum A, Dartigues JF. Modelling age-specific risk: application to dementia. Stat Med 1998;17:1973-1988.
11. Rapp SR, Espeland MA, Shumaker SA, et al. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 2003;289:2663-2672.
12. Shumaker SA, Legault C, Thal L, et al. Estrogen plus pro-gestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 2003;289:2651-2662.
13. Resnick SM, Maki PM, Rapp SR, et al. Effects of combination estrogen plus progestin hormone treatment on cognition and affect. J Clin Endocrinol Metab 2006;91: 1802-1810.
14. Hogervorst E, Williams J, Budge M, Riedel W, Jolles J. The nature of the effect of female gonadal hormone replacement therapy on cognitive function in post-menopausal women: a meta-analysis. Neuroscience 2000; 101:485-512.
15. Leblanc ES, Janowsky J, Chan BK, Nelson HD. Hormone replacement therapy and cognition: systematic review and meta-analysis. JAMA 2001;285:1489-1499.
16. Duff SJ, Hampson E. A beneficial effect of estrogen on working memory in postmenopausal women taking hormone replacement therapy. Horm Behav 2000;38:262-276.
17. Smith YR, Giordani B, Lajiness-O'Neill R, Zubieta JK. Long-term estrogen replacement is associated with improved nonverbal memory and attentional measures in postmenopausal women. Fertil Steril 2001;76:1101-1107.
18. Barrett-Connor E, Kritz-Silverstein D. Estrogen replacement therapy and cognitive function in older women. JAMA 1993;269:2637-2641.
19. Grodstein F, Chen J, Pollen DA, et al. Postmenopausal hormone therapy and cognitive function in healthy older women. J Am Geriatr Soc 2000;48:746-752.
20. L'Hermite M, Simoncini T, Fuller S, Genazzani AR. Could transdermal estradiol + progesterone be a safer postmenopausal HRT? A review. Maturitas 2008;60:185-201.
21. Schumacher M, Guennoun R, Ghoumari A, et al. Novel perspectives for progesterone in hormone replacement therapy, with special reference to the nervous system. En-docr Rev 2007;28:387-439.
22. Henderson VW, Benke KS, Green RC, Cupples LA, Far-rer LA. Postmenopausal hormone therapy and Alzheimer's disease risk: interaction with age. J Neurol Neurosurg Psychiatry 2005;76:103-105.
23. Bagger YZ, Tanko LB, Alexandersen P, Qin G, Christiansen C. Early postmenopausal hormone therapy may prevent cognitive impairment later in life. Menopause 2005;12:12-17.
24. MacLennan AH, Henderson VW, Paine BJ, et al. Hormone therapy, timing of initiation, and cognition in women aged older than 60 years: the REMEMBER pilot study. Menopause 2006;13:28-36.
25. Rocca WA, Bower JH, Maraganore DM, et al. Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause. Neurology 2007;69:1074-1083.
26. Kawas C, Resnick S, Morrison A, et al. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: the Baltimore Longitudinal Study of Aging. Neurology 1997;48:1517-1521.
27. Tang MX, Jacobs D, Stern Y, et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 1996;348:429-432.
28. Zandi PP, Carlson MC, Plassman BL, et al. Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study. JAMA 2002;288: 2123-2129.
29. Petitti DB, Crooks VC, Chiu V, Buckwalter JG, Chui HC. Incidence of dementia in long-term hormone users. Am J Epidemiol 2008;167:692-700.
30. Shumaker SA, Legault C, Kuller L, et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA 2004; 291:2947-2958.
31. Rippon GA, Tang MX, Lee JH, Lantigua R, Medrano M, Mayeux R. Familial Alzheimer disease in Latinos: interaction between APOE, stroke, and estrogen replacement. Neurology 2006;66:35-40.
32. Yun SH, Park KA, Kwon S, et al. Estradiol enhances long term potentiation in hippocampal slices from aged apoE4-TR mice. Hippocampus 2007;17:1153-1157.
33. Yaffe K, Haan M, Byers A, Tangen C, Kuller L. Estrogen use, APOE, and cognitive decline: evidence of gene-environment interaction Neurology 2000;54:1949-1954.
34. Burkhardt MS, Foster JK, Laws SM, et al. Oestrogen replacement therapy may improve memory functioning in the absence of APOE epsilon4. J Alzheimers Dis 2004;6: 221-228.
35. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
36. Isaacs B, Kennie AT. The Set Test as an aid to the detection of dementia in old people. Br J Psychiatry 1973;45: 957-962.
37. Benton AL. Manuel pour l'Application du Test de Retention Visuelle. Applications Cliniques et Experimentales. Paris: Centre de Psychologie Appliquee; 1965.
38. Dubois B. L'epreuve des cinq mots. Neurology Psychiatrie Geriatr 2001;1:40-42.
39. Reitan RM. Validity of the Trail Making Test as an indicator of organic brain damage. Percept Motor Skills 1965;8: 271-276.